CD274 and neoplasm: Combined use of IPI549 with anti-PDL1 antibodies increased susceptibility to anti-PDL1 therapy and enhanced radiotherapy-mediated immunogenic cell death by reprogramming the tumor microenvironment into an immunogenic phenotype [114].